These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29875430)

  • 1. A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.
    Burnett AK; Hills RK; Nielsen OJ; Freeman S; Ali A; Cahalin P; Hunter A; Thomas IF; Russell NH
    Leukemia; 2018 Dec; 32(12):2693-2697. PubMed ID: 29875430
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
    Russell NH; Hills RK; Kjeldsen L; Clark RE; Ali S; Cahalin P; Thomas IF; Burnett AK
    Br J Haematol; 2022 Aug; 198(3):528-534. PubMed ID: 35388465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
    Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
    Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
    Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
    Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population.
    Doan A; Huang HKT; Hadar AJ; Malvar J; Rushing T; Raca G; Kovach AE; Freyer DR; Parekh C; Stokke J; Posch LC; Dao J; Bhojwani D; Gaynon P; Orgel E
    Br J Haematol; 2023 Jul; 202(1):e3-e6. PubMed ID: 37129267
    [No Abstract]   [Full Text] [Related]  

  • 6. FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.
    Westhus J; Noppeney R; Dührsen U; Hanoun M
    Leuk Lymphoma; 2019 Apr; 60(4):1014-1022. PubMed ID: 30277107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The clinical comparison of FLAG regimen versus IA regimen for newly diagnosed acute myeloid leukemia].
    Yang B; Cao XS; Wang B
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):141-3. PubMed ID: 22730670
    [No Abstract]   [Full Text] [Related]  

  • 8. The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.
    Lee SR; Yang DH; Ahn JS; Kim YK; Lee JJ; Choi YJ; Shin HJ; Chung JS; Cho YY; Chae YS; Kim JG; Sohn SK; Kim HJ
    J Korean Med Sci; 2009 Jun; 24(3):498-503. PubMed ID: 19543516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].
    Qian SX; Li JY; Wu HX; Zhang R; Hong M; Xu W; Qiu HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):464-7. PubMed ID: 19379589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
    Short NJ; Kantarjian H; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Jabbour E
    Leuk Lymphoma; 2018 Apr; 59(4):813-820. PubMed ID: 28718728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
    Burnett AK; Russell NH; Hills RK; Hunter AE; Kjeldsen L; Yin J; Gibson BE; Wheatley K; Milligan D
    J Clin Oncol; 2013 Sep; 31(27):3360-8. PubMed ID: 23940227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients.
    Delia M; Pastore D; Carluccio P; Pasciolla C; Ricco A; Rossi AR; Casieri P; Mestice A; Albano F; Specchia G
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):767-773. PubMed ID: 28864170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia.
    Higashi Y; Turzanski J; Pallis M; Russell NH
    Br J Haematol; 2000 Nov; 111(2):565-9. PubMed ID: 11122104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
    Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
    J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
    Martínez Sánchez MP; Megías-Vericat JE; Rodríguez-Veiga R; Vives S; Bergua JM; Torrent A; Suárez-Varela S; Boluda B; Martínez-López J; Cano-Ferri I; Acuña-Cruz E; Torres-Miñana L; Martín-Herreros B; Serrano A; Sempere A; Barragán E; Sargas C; Sanz M; Martínez-Cuadrón D; Montesinos P;
    Ann Hematol; 2021 Jun; 100(6):1497-1508. PubMed ID: 33914097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.
    Kavanagh S; Heath E; Hurren R; Gronda M; Barghout SH; Liyanage SU; Siriwardena TP; Claudio J; Zhang T; Sukhai M; Stockley TL; Kamel-Reid S; Rostom A; Lutynski A; Khalaf D; Rydlewski A; Chan SM; Gupta V; Maze D; Sibai H; Schuh AC; Yee K; Minden MD; Schimmer AD
    Leuk Res; 2018 May; 68():22-28. PubMed ID: 29518628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [FLAG regimen as consolidation therapy for patients with acute myeloid leukemia].
    Qian SX; Wu HX; Hong M; Lu H; Xu W; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1577-81. PubMed ID: 20030951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
    Bergua JM; Montesinos P; Martinez-Cuadrón D; Fernández-Abellán P; Serrano J; Sayas MJ; Prieto-Fernandez J; García R; García-Huerta AJ; Barrios M; Benavente C; Pérez-Encinas M; Simiele A; Rodríguez-Macias G; Herrera-Puente P; Rodríguez-Veiga R; Martínez-Sánchez MP; Amador-Barciela ML; Riaza-Grau R; Sanz MA;
    Br J Haematol; 2016 Sep; 174(5):700-10. PubMed ID: 27118319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.
    Scappaticci GB; Marini BL; Nachar VR; Uebel JR; Vulaj V; Crouch A; Bixby DL; Talpaz M; Perissinotti AJ
    Ann Hematol; 2018 Apr; 97(4):573-584. PubMed ID: 29288428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.